Title: Co-Founder and Chief Scientific Officer
Organization: Kate Therapeutics
Presentations on early-stage research and development companies working on approaches to address the unmet therapeutic needs in the Duchenne community.
A moderated panel discussion focusing on the potential challenges and complications of AAV therapy and the clinical strategies to make dosing AAV more successful.
Professor and Associate Chair
University of Florida, Department of Pediatrics
Chief, Neuromuscular and Neurogenetic Disorders of Childhood Section National Institute of Neurological Disorders and Stroke/NIH
Director, Center for Gene Therapy Nationwide Children's Hospital
Co-Founder and Chief Scientific Officer
Kate Therapeutics
